Skip to main content
SpringerLink
Log in

Antineoplastische Substanzen

  • Chapter
Kompendium Internistische Onkologie

  • 106 Accesses

Zusammenfassung

Die systemische Therapie von fortgeschrittenen Tumorerkrankungen, aber auch die Therapie in der adjuvanten Konstellation, kann heute auf ein sehr breites und äußerst heterogenes Spektrum von Medikamenten zurückgreifen (Karp u. Broder 1994).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Binder C, Hiddemann W (1994) Programmed cell death — many questions still to be answered. Ann Hematol 60:45–55

    Article  Google Scholar 

  • Bohr VA (1994) Gene-specific damage and repair of DNA adducts and cross-links. In: Hemminki K, Dipple A, Shuker DEG, Kadlubar FF, Segerbäck D, Bartsch H (eds) DNA adducts: identification and biological significance. IARC Scientific Publications 125, Oxford Univ Press, Lyon, pp 361–369

    Google Scholar 

  • Cabral F, Barlow SB (1989) Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 3:1593–1599

    PubMed  CAS  Google Scholar 

  • Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517–1524

    Article  PubMed  CAS  Google Scholar 

  • Chu G (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269:787–790

    PubMed  CAS  Google Scholar 

  • Cody V, Wojtczak A, Kaiman TI, Friesheim JH, Blakley RL (1993) Conformational analysis of human dihydrofolate reductase inhibitor complexes: crystal structure determination of wild type and F31 mutant binary and ternary inhibitor complexes. Adv Exp Med Biol 338:481–486

    Article  PubMed  CAS  Google Scholar 

  • D’Arpa P, Leroy FL (1989) Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989:163–177

    PubMed  Google Scholar 

  • De Vita VT Jr (1993) Principles of Chemotherapie. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. Lippincott, Philadelphia, pp 276–292

    Google Scholar 

  • Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C, Hickman JA (1993) bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer 53:3321–3326

    CAS  Google Scholar 

  • Gabius HJ, Gabius S (1994) Wohin führt die naturwissenschaftliche Forschung über Misteltherapie? Dtsch Ärztebl 91:1743–1774

    Google Scholar 

  • Goldman D, Matherly LH (1985) The cellular pharmacology of methotrexate. Pharmacol Ther 25:77–102

    Article  Google Scholar 

  • Grindey GB (1990) Current status of cancer drug development: failure of limited success? Cancer Cells 2:163–170

    PubMed  CAS  Google Scholar 

  • Hartley JA, Souhami RL (1992) DNA-sequence specificity of anticancer agents. In: Hickman JA, Tritton TR (eds) Cancer chemotherapy. Blackwell, London pp 251–280

    Google Scholar 

  • Karp JE, Broder S (1994) New directions in molecular medicine. Cancer 54:653–665

    CAS  Google Scholar 

  • Kirkland MA (1994) Antisense therapeutics in haematological malignancies. Br J Haematol 87:447–452

    Article  PubMed  CAS  Google Scholar 

  • Lacombe F, Belloc F, Dumain P et al. (1992) Quantitation of resistance of leukemic cells to cytosine arabinoside from BrdUrd/DNA bivariate histograms. Cytometry 13:730–738

    Article  PubMed  CAS  Google Scholar 

  • Leteurtre F, Kohlhagen G, Pauli KD, Pommier Y (1994) Topoisomerase II inhibition and cytotoxicity of the antrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J Natl Cancer Inst 86:1239–1244

    Article  PubMed  CAS  Google Scholar 

  • Lotem J, Sachs L (1993) Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 4:41–47

    PubMed  CAS  Google Scholar 

  • McKelvey-Martin VJ, Green MHL, Schmezer P, Pool-Zobel BL, De Méo MP, Collins A (1993) The single cell gel electrophoresis assay (comet assay): a european review. Mutat Res 2288:46–63

    Google Scholar 

  • Merkel DE, McGuire WL (1990) Ploidy, proliferative activity, and prognosis. Cancer 65:1194–1205

    Article  PubMed  CAS  Google Scholar 

  • Miyashita T, Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151–157

    PubMed  CAS  Google Scholar 

  • Olive PL, Durand RE, Le Riche J, Olivotto IA, Jackson SM (1993) Gel electrophoresis of individual cells to quantify hypoxic fraction in human breath cancers. Cancer Res 53:733–736

    PubMed  CAS  Google Scholar 

  • Oshita F, Eastman A (1993) Gene-specific damage produced by cisplatin, ormaplatin and UV light in human cells as assayed by the polymerase chain reaction. Oncol Res 5:111–118

    PubMed  CAS  Google Scholar 

  • Pauli KD, Hamel E, Malspeis L (1994) Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute (in press)

    Google Scholar 

  • Pendergast PS, Ebright YW, Ebright RH (1994) High-specificity DNA cleavage agent: design and application to kilobase and megabase DNA substrates. Science 265:959–962

    Article  Google Scholar 

  • Sato T, Hanada M, Bodrug S et al. (1994) Interactions among members of the Bcl-2 protein family analyzed with yeast two-hybrid system. Proc Natl Acad Sci USA 91:9238–9242

    Article  PubMed  CAS  Google Scholar 

  • Shen CC, Shen CK (1990) Specificity and flexibility of the recognition of DNA helical structure by eukaryotic topoisomerase I. J Mol Biol 212:67–78

    Article  PubMed  CAS  Google Scholar 

  • Sobrero AF, Aschele C, Guglielmi AP et al. (1993) Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 85:1937–1944

    Article  PubMed  CAS  Google Scholar 

  • Spitzner JR, Muller MT (1988) A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res 16:5533–5556

    Article  PubMed  CAS  Google Scholar 

  • Stewart BW (1994) Mechanisms of apoptosis: Integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 86:1286–1296

    Article  PubMed  CAS  Google Scholar 

  • Szilvassy SJ, Cory S (1994) Efficient retroviral gene transfer to purified long-term repopulating hematopoietic stem cells. Blood 84:74–83

    PubMed  CAS  Google Scholar 

  • Tang C, Willingham MC, Reed JC et al. (1994) High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960–1969

    PubMed  CAS  Google Scholar 

  • van Houten B, Snowden A (1993) Mechanism of action of the Escherichia coli UvrABC nuclease: Clues to the damage recognition problem. Bioessays 15/1:51–59

    Article  PubMed  Google Scholar 

Literatur

  • Clark PI, Joel SP, Slevin ML (1989) A pharmacokinetic hypothesis for the clinical efficacy of etoposide in small-cell lung cancer. Proc ASCO 8:66

    Google Scholar 

  • D’Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Prog Biomed 9:115–134

    Article  Google Scholar 

  • Jodrell DI, Reyno LM, Sridhara R et al. (1994) Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 12:166–175

    PubMed  CAS  Google Scholar 

  • Newell DR (1994) Can pharmacokinetic and pharmacodynamic studies improve cancer chemotherapy? Ann Oncol 5 [Suppl 4]: S9–S15

    Google Scholar 

  • Ratain MJ, Schilsky RL, Choi KE at al. (1989) Adaptive control of etoposide dosing: Impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 45:226–233

    Article  PubMed  CAS  Google Scholar 

  • Ratain MJ, Schilsky RL, Conley BA et al. (1990) Pharmacodynamics in cancer therapy. J Clin Oncol 8:1739–1753

    PubMed  CAS  Google Scholar 

  • Santini J, Milano G, Thyss A et al. (1989) 5-FU therapeutic monitoring with dose adjustments leads to improved therapeutic index in head and neck cancer. Br J Cancer 59:287–290

    Article  PubMed  CAS  Google Scholar 

  • Stewart CF, Arbuck SG, Fleming RA et al. (1991) Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 50:385–393

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Boros L, Cacek T, Pine RB, Battaglia AC (1992) Distribution characteristics of mitoxantrone in a patient undergoing hemodialysis. Cancer Chemother Pharmacol 31:57–60

    Article  PubMed  CAS  Google Scholar 

  2. Cobos E, Hall RR (1993) Effects of chemotherapy on the kidney. Semin Nephrol 13:297–305

    PubMed  CAS  Google Scholar 

  3. Füger K, Blumenstein M, Sauer H (1990) Dialysierbarkeit von Zytostatika. Experimentelle Untersuchungen in vitro. Onkologie 13:289–294

    Article  PubMed  Google Scholar 

  4. Gordon TR, Lindley CM, Tremont SJ (1992) Cisplatin-based chemotherapy in a renal transplant recipient. Reply to Vogelzang. Cancer 69:3015–3016

    Article  Google Scholar 

  5. Hande KR (1993) Pharmacologic-based dosing of carboplatin: a better method. J Clin Oncol 11:2295–2296

    PubMed  CAS  Google Scholar 

  6. Kobayashi K, Ratain MJ (1993) Individualizing dosing of cancer chemotherapy. Semin Oncol 20:30–42

    PubMed  CAS  Google Scholar 

  7. Koren G, Beatty K, Seto A, Einarson TR, Lishner M (1992) The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 26:363–371

    PubMed  CAS  Google Scholar 

  8. Liliemark J, Peterson C (1991) Pharmacokinetic optimisation of anticancer therapy. Clin Pharmacokinet 21:213–231

    Article  PubMed  CAS  Google Scholar 

  9. Lindley CM, Gordon TR, Tretmont SJ (1991) Cisplatin-based chemotherapy in a renal transplant recipient. Cancer 68:1113–1117

    Article  PubMed  CAS  Google Scholar 

  10. Patterson WP, Reams GP (1992) Renal toxicities of chemotherapy. Semin Oncol 19:521–528

    PubMed  CAS  Google Scholar 

  11. Perry MC (1992) Chemotherapeutic agents and hepatotoxicity. Sem Oncol 19:551–565

    CAS  Google Scholar 

  12. Reilly JJ, Workman P (1993) Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? Cancer Chemother Pharmacol 32:411–418

    Article  PubMed  CAS  Google Scholar 

  13. Ribrag V, Droz JP, Morizet J, Leclercq B, Gouyette A, Chabot GG (1993) Test dose-guided administration of cisplatin in an anephric patient: a case report. Ann Oncol 4:679–682

    PubMed  CAS  Google Scholar 

  14. Sauer H (1991) Zytostatikatherapie beim alten Menschen. Internist 32:479–485

    PubMed  CAS  Google Scholar 

  15. Sauer H (1993) Tumorkrankheiten im höheren Lebensalter. Der Bay. Int. 13 (Sonderausgabe „Therapieforschung“): 19–24

    Google Scholar 

  16. Sauer H, Wilmanns W (1991) Internistische Therapie maligner Erkrankungen, 3. Auflage 1991, Urban & Schwarzenberg, München Wien Baltimore

    Google Scholar 

  17. Sauer H, Wilmanns W (1993) Zytostatika-Therapie. S.295–317. In: Platt D (Hrsg) Pharmakotherapie und Alter, 2. Aufl. Springer, Berlin Heidelberg New York Tokyo

    Chapter  Google Scholar 

  18. Smith TJ, Desch CE (1991) Neutropenia-wise and pound-foolish: safe and effective chemotherapy in massively obese patients. South Med J 84:883–885

    Article  PubMed  CAS  Google Scholar 

  19. Teneriello M, Farley J, Parker M, O’Connor D, Shaver T, Park R, Barnhill D (1993) Management of advanced ovarian epithelial cancer in the renal transplant patient. Gynecol Oncol 50:374–378

    Article  PubMed  CAS  Google Scholar 

  20. Twelves CJ, Dobbs NA, Michael Y, Summers LA, Gregory W, Harper PG (1992) Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 66:765–769

    Article  PubMed  CAS  Google Scholar 

  21. Vogelzang NJ (1990) Cisplatin and etoposide for metastatic testis cancer in a renal transplant recipient. J Urol 143:1235–1236

    PubMed  CAS  Google Scholar 

  22. Vogelzang NJ (1992) Cisplatin-based chemotherapy in a renal transplant recipient. Cancer 69:3015

    Article  PubMed  CAS  Google Scholar 

Literatur

  • ASHP Reports (1985) ASHP technical assistance bulltein on handling cytotoxic drugs in hospitals. Am J Hosp Pharm 42/1

    Google Scholar 

    Google Scholar 

  • Bundesverband der Unfallversicherungsträger der öffentlichen Hand BAGUV (1983) Merkblatt Sichere Handhabung von Zytostatika. Ausgabe März

    Google Scholar 

  • D’Arcy PF (ed) Drug interactions and reactions update. Drug Intelligence Clin Pharmacol 17

    Google Scholar 

  • Donislawski S, Meier K (1991) Überlegungen zur Verbesserung des Arbeitsschutzes beim Umgang mit gefährlichen Arzneimitteln. Pharm Ztg Wiss 136/2(4)

    Google Scholar 

    Google Scholar 

  • Falck K et al. (1979) Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 2:1250

    Article  Google Scholar 

  • Hirst M et al. (1984) Occupational exposure to cyclophosphamide. Lancet

    Google Scholar 

  • Illiger HJ, Hartlapp JH (1984) Pharmazeutische, pharmakokinetische und -dynamische Interaktionen bei der medikamentösen Tumortherapie. Onkologie 7 [Suppl 1]:10–18

    Article  PubMed  CAS  Google Scholar 

  • Obrist R, Obrecht JP (1984) Zytostatika: Gefährdung für Schwestern und Ärzte? MMW 126/17

    Google Scholar 

    Google Scholar 

  • Schaaf DE, Schott E (1984) Entsorgung und Vernichtung von Zytostatikaabfällen. Krankenhauspharmazie 5/10

    Google Scholar 

    Google Scholar 

  • Schaaf DE, Schott E, Grimm H (1984) Vorsichts- und Schutzmaßnahmen beim Umgang mit Zytostatika. Krankenhauspharmazie 5/9

    Google Scholar 

    Google Scholar 

  • Schmidt B (1985) Sind Maßnahmen zum Schutze des Pflegepersonals im Umgang mit Zytostatika notwendig? SAKK Bulletin, Quartal I

    Google Scholar 

  • Sotaniemi EA et al. (1983) Liver damage in nurses handling cytostatic agents. Acta Med Scand 214:181–189

    Article  PubMed  CAS  Google Scholar 

  • Stellman JM et al. (1984) Assessment of potential exposure of antineoplastic agents in the health care setting. Prev Med 13:245–255

    Article  PubMed  CAS  Google Scholar 

  • Talok et al. (1979) Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 2:1250

    Google Scholar 

Literatur

  • Averbuch SD, Gaudiano G, Koch TH, Bachur NR (1986) Doxorubicin induced skin necrosis in the swine model: protection with a novel radical dimer. J Clin Oncol 4:88–94

    PubMed  CAS  Google Scholar 

  • Barr RD, Sertic J (1981) Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: a study of active intervention. Cancer 44:267–269

    Article  CAS  Google Scholar 

  • Barlock AL, Howser DM, Hubbard SM (1979) Nursing management of adriamycin extravasation. Am J Nurs 79:94–96

    PubMed  CAS  Google Scholar 

  • Cox K, Stuart-Harris R, Abdini G, Grygiel J, Raghavan D (1988) The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148:185–189

    PubMed  CAS  Google Scholar 

  • Doll DC, Ringenberg QS, Yarbro JW (1986) Vascular toxicity associated with antineoplastic agents. J Clin Oncol 4:1405–1417

    PubMed  CAS  Google Scholar 

  • Dorr RT (1990) Antidotes to vesicant chemotherapy extravasations. Blood Rev 4:41–60

    Article  PubMed  CAS  Google Scholar 

  • Dorr RT, Albert DS (1981) Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds. Cancer Treat Rep 65:1001–1006

    PubMed  CAS  Google Scholar 

  • Dorr RT, Fritz WL (1981) Cancer chemotherapy handbook (insbesondere Kap. 5 und 9). Elsevier North Holland, New-York Oxford

    Google Scholar 

  • Gallina EJ (1993) Practical guide to chemotherapy administration for physicians and oncology nurses. In: Vincent T, de Vita Jr, Hellman S, Steven A, Rosenberg (eds) Cancer: Principles and practice of oncology, 4th edn. Lippincott, Philadelphia, pp 2570–2580

    Google Scholar 

  • Ignoffo RJ, Friedman MA (1980) Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 64:17–27

    Article  Google Scholar 

  • Köstering H, Nagel GA (1980) Prophylaxe und Therapie von Zytostatika-Hautnekrosen. Onkologie 3:317–320

    Article  PubMed  Google Scholar 

  • Larson DL (1982) Treatment of tissue extravasation by antitumor agents. Cancer 49:1796–1799

    Article  PubMed  CAS  Google Scholar 

  • Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF, Kaplan RS (1988) A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 6:1732–1735

    PubMed  CAS  Google Scholar 

  • Perry MC, Yarbo JW (1984) Toxicity of chemotherapy (insbesondere Kapitel 5 und 19). Grune & Stratton, Orlando San Diego

    Google Scholar 

  • Rudolph R, Larson DL (1987) Etiology and treatment of chemotherapeutic agent extravasation injuries: A review. J Clin Oncol 5:1116–1126

    PubMed  CAS  Google Scholar 

  • Van Sloten K, Harwood K, Aisner J (1984) Treatment of chemotherapy extravasation: Current status. Cancer Treat Rep 68:939–945

    Google Scholar 

Download references

Authors
  1. R. Osieka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Efferth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Borner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Cerny
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Sauter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Barth
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Schneemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Sauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H.-J. Illiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L. Bornmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A. Laupert
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H.-L. Illiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. W. E. Berdel
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H.-J. Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Hämatologie/Onkologie, Martin-Luther-Universitä Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle/Saale, Deutschland

    Hans-Joachim Schmoll

  2. Klinik und Poliklinik für Innere Medizin II, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07740, Jena, Deutschland

    Klaus Höffken

  3. Medizinischen Klinik II Schwerpunkt Onkologie und Hämatologie, Humboldt-Universität, Universitätsklinikum Charité, Schumannstraße 20/21, 10117, Berlin, Deutschland

    Kurt Possinger (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Heidelberg

About this chapter

Cite this chapter

Osieka, R. et al. (1996). Antineoplastische Substanzen. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79214-4_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-79214-4_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58370-7

  • Online ISBN: 978-3-642-79214-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation